Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial examining the addition of DT2216 to standard chemotherapy for relapsed or refractory solid tumors and fibrolamellar carcinoma in childr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrolamellar Hepatocellular Carcinoma

Drugs mentioned

• DT2216

Snippet

Sponsor: Children's Oncology Group | Conditions: Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma | Phase 1, Phase 2 | Status: RECRUITING